As part of its $1.415 billion settlement for off-label marketing of Zyprexa, Eli Lilly & Co. will enter a Corporate Integrity Agreement with the HHS Office of Inspector General.
The agreement requires that Lilly: send doctors letters advising them of the settlement and giving them a means of reporting questionable conduct by sales reps; list payments to doctors on its website; and that its board and senior management regularly certify that the company is in compliance and has an effective program to stay that way.
As part of its $62 million October settlement with 32 states and the District of Columbia, Lilly agreed to furnish those state’s attorney generals with a list of all healthcare professionals paid more than $100 for promotional speaking and consulting in the US. Lilly had previously announced that it would report payments to physicians of over $500 as part of a transparency initiative.
Lilly’s agreement with the states, binding until 2014, includes provisions governing promotional activities, dissemination of medical information, CME grants, payments to consultants and speakers, sampling and clinical research and stipulates areas and activities which are off-limits to Lilly sales and marketing teams.
